Skip to main content

Table 1 Baseline characteristics of study participants

From: Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation

Variable n (%) Median (Range)
Male sex 24 (57.1)  
Diagnosis   
   de novo AML 17 (40.5)  
   ALL 12 (28.6)  
   CML-AP 2 (4.8)  
   MDS overt AML 10 (23.8)  
   PCL 1 (2.4)  
Cytogenetics   
   Intermediate 17  
   Poor 22  
ECOG PS   
   0 2 (4.8)  
   1 25 (59.5)  
   2 7 (16.7)  
   3 8 (19.0)  
Status at allo-HCT   
   Primary refractory/Refractory relapse/Untreated MDS overt AML 7/32/3  
No. chemo regimens prior allo-HCT   6 (0-18)
Time from diagnosis to allo-HCT (days)   319 (23-3738)
Marrow blasts at allo-HCT   26.0 (0.2-100)
Conditioning regimen   
   Intensified 9 (21.4)  
   Standard 12 (28.6)  
   Reduced-intensity 7 (16.7)  
   Reduced-intensity + cytoreductive chemotherapy 14 (33.3)  
GVHD prophylaxis   
   None 3 (7.1)  
   Calcineurin inhibitor alone 5 (11.9)  
   Calcineurin inhibitor + sMTX 32 (76.2)  
   Calcineurin inhibitor + MMF 2 (4.8)  
Donor (HLA-A, B and DRB1 antigens)   
   Matched related PB/BM 10/2  
   Mismatched related PB/BM 3/1  
   Matched unrelated BM 19  
   Mismatched unrelated BM 1  
   Umbilical cord blood 6  
  1. allo-HCT: allogeneic hematopoietic cell transplantation; HLA: human leukocyte antigen; sMTX: short-term methotrexate; MMF: mycophenolate motefil; BM: bone marrow; PB: peripheral blood.